Categories: Wire Stories

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the Company’s novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332.

ICP-332 is a potent and selective TYK2 inhibitor. ICP-332 achieved multiple efficacy endpoints in the China Phase II study for the treatment of patients with moderate-to-severe atopic dermatitis (AD), demonstrating an outstanding efficacy and safety profile. ICP-332 showed better efficacy profile across different classes/MoAs of therapies for the treatment of AD patients (not a head-to-head comparison). The detailed data was presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting as a late-breaking oral presentation.

Currently, no TYK2 inhibitors have obtained marketing approval for the treatment of AD anywhere in the world. As a non-receptor tyrosine kinase, TYK2 is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway and plays an important role in the pathogenesis of inflammatory diseases.

Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, “InnoCare is dedicated to targeting the global frontier in autoimmune therapy by focusing on B-cell and T-cell pathways. We have developed robust pipeline of differentiated therapeutics for autoimmune disease with significant market potential worldwide, including orelabrutinib (BTK inhibitor), ICP-332 (TYK2-JH1 inhibitor), ICP-488 (TYK2-JH2 inhibitor) and ICP-923 (IL-17 small molecule inhibitor). We are committed to accelerating clinical development and look forward to our innovative drugs benefiting patients with autoimmune diseases as early as possible.”

About InnoCare

InnoCare (HKEX: 09969; SSE: 688428) is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases with unmet medical needs in China and worldwide. InnoCare has branches in Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and United States.

Contacts

Media
Chunhua Lu

86-10-66609879

chunhua.lu@innocarepharma.com

Investors
86-10-66609999

ir@innocarepharma.com

Alex

Recent Posts

Michelin Showcases Its Commitment to Innovating for a Sustainable Future at Asia Pacific Media Day 2024 in Thailand

BANGKOK, THAILAND - Media OutReach Newswire - 22 November 2024 - Michelin, world-leading manufacturer of…

1 hour ago

Elsie’s Kitchen Unveils Christmas Catering Menus to Elevate Holiday Celebrations

SINGAPORE - Media OutReach Newswire - 22 November 2024 - Elsie's Kitchen is thrilled to…

2 hours ago

PT. Eka Mas Republik (MyRepublic) Celebrates Double Recognition at ACES Awards

BANGKOK, THAILAND - Media OutReach Newswire - 22 November 2024 - PT. Eka Mas Republik,…

3 hours ago

Hong Kong’s premier ink art event UOB Art in Ink Festival returns this December, fostering art inclusivity

HONG KONG SAR - Media OutReach Newswire - 21 November 2024 - UOB Art Academy…

14 hours ago

Arbor Partners With Japanese Aomori Prefecture To Unveil A New Japanese-French Culinary Feast

HONG KONG SAR - Media OutReach Newswire - 21 November 202 - Aomori Crafts from…

15 hours ago

Beloved Disney ∙ Pixar Characters Come to Life as 10 FURRY NICE Collectible Furry Friend Sets at 7-Eleven

Collect FunStamps on the New 7-Eleven App and Redeem for FREE HONG KONG SAR -…

15 hours ago